Risk factors for carbapenem-resistant Enterobacteriaceae infections: a French case-control-control study.
Adult
Aged
Aged, 80 and over
Anti-Bacterial Agents
/ pharmacology
Bacterial Proteins
/ biosynthesis
Carbapenem-Resistant Enterobacteriaceae
/ drug effects
Case-Control Studies
Enterobacteriaceae
/ drug effects
Enterobacteriaceae Infections
/ drug therapy
Female
France
/ epidemiology
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Risk Factors
beta-Lactamases
/ biosynthesis
Carbapenem-resistant Enterobacteriaceae (CRE)
Carbapenemase-producing Enterobacteriaceae (CPE)
Case-control-control study
Multicentre study
Risk factors
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
Feb 2019
Feb 2019
Historique:
received:
09
10
2018
accepted:
19
11
2018
pubmed:
30
11
2018
medline:
6
5
2019
entrez:
30
11
2018
Statut:
ppublish
Résumé
This study aimed to assess characteristics associated with infections due to carbapenem-resistant Enterobacteriaceae (CRE), producing (CPE) or not producing (non-CPE) carbapenemase, among hospitalised patients in 2014-2016 in France. Case-patients with CRE were compared to two control populations. In multivariate analysis comparing 160 CRE cases to 160 controls C1 (patients with a clinical sample positive for carbapenem-susceptible Enterobacteriaceae), five characteristics were linked to CRE: male gender (OR = 1.9; 95% CI = 1.3-3.4), travel in Asia (OR = 10.0; 95% CI = 1.1-91.2) and hospitalisation in (OR = 2.4; 95% CI = 1.3-4.4) or out of (OR = 4.4; 95% CI = 0.8-24.1) France in the preceding 12 months, infection in the preceding 3 months (OR = 3.0; 95% CI = 1.5-5.9), and antibiotic receipt between admission and inclusion (OR = 1.9; 95% CI = 1.0-3.3). In multivariate analysis comparing 148 CRE cases to 148 controls C2 [patients with culture-negative sample(s)], four characteristics were identified: prior infection (OR = 3.3; 95% CI = 1.6-6.8), urine drainage (OR = 3.0; 95% CI = 1.5-6.1) and mechanical ventilation (OR = 3.7; 95% CI = 1.1-13.0) during the current hospitalisation, and antibiotic receipt between admission and inclusion (OR = 6.6; 95% CI = 2.8-15.5). Univariate analyses comparing separately CPE cases to controls (39 CPE vs C1 and 36 CPE vs C2) and non-CPE cases to controls (121 non-CPE vs C1 and 112 non-CPE vs C2), concomitantly with comparison of CPE to non-CPE cases showed that only CPE cases were at risk of previous travel and hospitalisation abroad. This study shows that, among CRE, risk factors are different for CPE and non-CPE infection, and suggests that question patients about their medical history and lifestyle should help for early identification of patients at risk of CPE among patients with CRE.
Identifiants
pubmed: 30488368
doi: 10.1007/s10096-018-3438-9
pii: 10.1007/s10096-018-3438-9
doi:
Substances chimiques
Anti-Bacterial Agents
0
Bacterial Proteins
0
beta-Lactamases
EC 3.5.2.6
carbapenemase
EC 3.5.2.6
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
383-393Subventions
Organisme : Ministère de la Sané (Programme de recherche clinique hospitalière
ID : NI12025
Investigateurs
Caroline Laurans
(C)
Anne Vachée
(A)
Nadine Lemaître
(N)
Alix Pantel
(A)
Jean-Philippe Lavigne
(JP)
Laurent Cavalie
(L)
Nicole Marty
(N)
Xavier Bertrand
(X)
Christophe De Champs
(C)
Odile Bajolet
(O)
Anne Limelette
(A)
Stéphane Corvec
(S)
Céline Bourigault
(C)
Didier Lepelletier
(D)
Nathalie van der Mee-Marquet
(N)
Audrey Merens
(A)
Etienne Carbonnelle
(E)
Typhaine Billard-Pomares
(T)
Fréderic Bert
(F)
Véronique Leflon-Guibout
(V)
Marion Duprilot
(M)
Simone Nérome
(S)
Emmanuelle Cambau
(E)
Hervé Jacquier
(H)
Hana Benmansour
(H)
Vincent Jarlier
(V)
Emilie Lafeuille
(E)
Dominique Decré
(D)
Références
Clin Infect Dis. 2001 Apr 1;32(7):1055-61
pubmed: 11264034
Curr Opin Infect Dis. 2001 Dec;14(6):697-701
pubmed: 11964887
Lancet Infect Dis. 2008 Mar;8(3):159-66
pubmed: 18291338
JAMA. 2008 Dec 24;300(24):2911-3
pubmed: 19109119
Antimicrob Agents Chemother. 2010 May;54(5):2119-24
pubmed: 20211892
Clin Infect Dis. 2011 Apr 1;52(7):848-55
pubmed: 21317398
Emerg Infect Dis. 2011 Oct;17(10):1791-8
pubmed: 22000347
J Travel Med. 2012 Sep-Oct;19(5):320-3
pubmed: 22943275
J Antimicrob Chemother. 2014 Feb;69(2):559-60
pubmed: 24013194
Euro Surveill. 2014 Apr 10;19(14):null
pubmed: 24739981
J Antimicrob Chemother. 2014 Oct;69(10):2706-12
pubmed: 24942333
Eur J Clin Microbiol Infect Dis. 2014 Dec;33(12):2285-92
pubmed: 25037867
Int J Antimicrob Agents. 2015 Apr;45(4):445-6
pubmed: 25631676
Infect Dis (Lond). 2015 Aug;47(8):593-5
pubmed: 25751777
Eur J Clin Microbiol Infect Dis. 2015 Jun;34(6):1263-9
pubmed: 25759112
PLoS One. 2015 Mar 20;10(3):e0121668
pubmed: 25794144
Acta Clin Belg. 2015 Jun;70(3):181-7
pubmed: 25825036
Clin Infect Dis. 2015 Aug 15;61(4):593-600
pubmed: 25904368
J Travel Med. 2015 Sep-Oct;22(5):292-9
pubmed: 25997830
JAMA. 2015 Oct 13;314(14):1479-87
pubmed: 26436831
Expert Rev Anti Infect Ther. 2016;14(1):95-108
pubmed: 26535959
Eur J Clin Microbiol Infect Dis. 2016 Mar;35(3):379-85
pubmed: 26740321
J Investig Med. 2016 Jun;64(5):1042-9
pubmed: 27101841
Future Microbiol. 2016 Jul;11:857-64
pubmed: 27357522
J Infect Public Health. 2017 Nov - Dec;10(6):716-720
pubmed: 28216021
J Infect Dis. 2017 Feb 15;215(suppl_1):S28-S36
pubmed: 28375512
Euro Surveill. 2017 May 11;22(19):
pubmed: 28537547
Sci Rep. 2017 Jul 27;7(1):6722
pubmed: 28751669
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29038269
Euro Surveill. 2018 Feb;23(8):
pubmed: 29486831